Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
21
LAB Quote, Financials, Valuation and Earnings
Last price:
$1.14
Seasonality move
:
-3.5%
Day range:
$1.11 - $1.18
52-week range:
$0.92 - $1.72
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.32x
P/B ratio:
1.09x
Volume:
2.7M
Avg. volume:
1.5M
1-year change:
-16.3%
Market cap:
$434.6M
Revenue:
$174.4M
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$18.5M | -$0.03 | -54.41% | -72.53% | $1.55 |
|
LNSR
LENSAR, Inc.
|
$20.5M | -$0.09 | 30.98% | -90.51% | $15.00 |
|
LUDG
Ludwig Enterprises, Inc.
|
-- | -- | -- | -- | -- |
|
OPGN
OpGen, Inc.
|
-- | -- | -- | -- | -- |
|
USAQ
QHSLab, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$1.13 | $1.55 | $434.6M | -- | $0.00 | 0% | 3.32x |
|
LNSR
LENSAR, Inc.
|
$11.69 | $15.00 | $139.6M | -- | $0.00 | 0% | 2.34x |
|
LUDG
Ludwig Enterprises, Inc.
|
$0.0221 | -- | $3.6M | -- | $0.00 | 0% | 37,130.15x |
|
OPGN
OpGen, Inc.
|
$23.9900 | -- | $241.6M | 59.99x | $0.00 | 0% | 26.93x |
|
USAQ
QHSLab, Inc.
|
$0.6734 | -- | $7.6M | -- | $0.00 | 0% | 3.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
6.41% | 0.841 | 5.49% | 1.93x |
|
LNSR
LENSAR, Inc.
|
-31.16% | -1.239 | 1.79% | 0.65x |
|
LUDG
Ludwig Enterprises, Inc.
|
-144.65% | -0.654 | 24.05% | 0.00x |
|
OPGN
OpGen, Inc.
|
16.9% | -36,920.421 | 205167.16% | 5.70x |
|
USAQ
QHSLab, Inc.
|
162.97% | -1.888 | 73.75% | 0.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LAB
Standard BioTools, Inc.
|
$9.5M | -$23.5M | -22.34% | -24.44% | -120.02% | -$23.1M |
|
LNSR
LENSAR, Inc.
|
$5.8M | -$7.6M | -684.94% | -1013.45% | -52.95% | -$3.5M |
|
LUDG
Ludwig Enterprises, Inc.
|
-- | -$371.4K | -- | -- | -419868.12% | -$139.1K |
|
OPGN
OpGen, Inc.
|
-$48.1K | -$702.2K | 70.06% | 89.47% | -5625.96% | -$333.3K |
|
USAQ
QHSLab, Inc.
|
$475.6K | $96.3K | -35.74% | -- | 13.05% | $2.6K |
Standard BioTools, Inc. vs. Competitors
-
Which has Higher Returns LAB or LNSR?
LENSAR, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -25.94%. Standard BioTools, Inc.'s return on equity of -24.44% beat LENSAR, Inc.'s return on equity of -1013.45%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M LNSRLENSAR, Inc.40.56% -$0.31 -$9.2M -
What do Analysts Say About LAB or LNSR?
Standard BioTools, Inc. has a consensus price target of $1.55, signalling upside risk potential of 37.17%. On the other hand LENSAR, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 28.32%. Given that Standard BioTools, Inc. has higher upside potential than LENSAR, Inc., analysts believe Standard BioTools, Inc. is more attractive than LENSAR, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 LNSRLENSAR, Inc.0 2 0 -
Is LAB or LNSR More Risky?
Standard BioTools, Inc. has a beta of 1.290, which suggesting that the stock is 28.967% more volatile than S&P 500. In comparison LENSAR, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.253%.
-
Which is a Better Dividend Stock LAB or LNSR?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. LENSAR, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or LNSR?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than LENSAR, Inc. quarterly revenues of $14.3M. Standard BioTools, Inc.'s net income of -$31.7M is lower than LENSAR, Inc.'s net income of -$3.7M. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while LENSAR, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.32x versus 2.34x for LENSAR, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.32x -- $19.6M -$31.7M LNSRLENSAR, Inc.2.34x -- $14.3M -$3.7M
-
Which has Higher Returns LAB or LUDG?
Ludwig Enterprises, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -427991.3%. Standard BioTools, Inc.'s return on equity of -24.44% beat Ludwig Enterprises, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M LUDGLudwig Enterprises, Inc.-- -- -$1.4M -
What do Analysts Say About LAB or LUDG?
Standard BioTools, Inc. has a consensus price target of $1.55, signalling upside risk potential of 37.17%. On the other hand Ludwig Enterprises, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Standard BioTools, Inc. has higher upside potential than Ludwig Enterprises, Inc., analysts believe Standard BioTools, Inc. is more attractive than Ludwig Enterprises, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 LUDGLudwig Enterprises, Inc.0 0 0 -
Is LAB or LUDG More Risky?
Standard BioTools, Inc. has a beta of 1.290, which suggesting that the stock is 28.967% more volatile than S&P 500. In comparison Ludwig Enterprises, Inc. has a beta of 2.470, suggesting its more volatile than the S&P 500 by 146.979%.
-
Which is a Better Dividend Stock LAB or LUDG?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ludwig Enterprises, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. Ludwig Enterprises, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or LUDG?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than Ludwig Enterprises, Inc. quarterly revenues of --. Standard BioTools, Inc.'s net income of -$31.7M is lower than Ludwig Enterprises, Inc.'s net income of $31.3K. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while Ludwig Enterprises, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.32x versus 37,130.15x for Ludwig Enterprises, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.32x -- $19.6M -$31.7M LUDGLudwig Enterprises, Inc.37,130.15x -- -- $31.3K
-
Which has Higher Returns LAB or OPGN?
OpGen, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of -5629.82%. Standard BioTools, Inc.'s return on equity of -24.44% beat OpGen, Inc.'s return on equity of 89.47%.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M OPGNOpGen, Inc.55.51% -$0.06 $12.2M -
What do Analysts Say About LAB or OPGN?
Standard BioTools, Inc. has a consensus price target of $1.55, signalling upside risk potential of 37.17%. On the other hand OpGen, Inc. has an analysts' consensus of -- which suggests that it could grow by 25.05%. Given that Standard BioTools, Inc. has higher upside potential than OpGen, Inc., analysts believe Standard BioTools, Inc. is more attractive than OpGen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 OPGNOpGen, Inc.0 0 0 -
Is LAB or OPGN More Risky?
Standard BioTools, Inc. has a beta of 1.290, which suggesting that the stock is 28.967% more volatile than S&P 500. In comparison OpGen, Inc. has a beta of -3,423.037, suggesting its less volatile than the S&P 500 by 342403.692%.
-
Which is a Better Dividend Stock LAB or OPGN?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OpGen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. OpGen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or OPGN?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than OpGen, Inc. quarterly revenues of --. Standard BioTools, Inc.'s net income of -$31.7M is lower than OpGen, Inc.'s net income of -$608.7K. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while OpGen, Inc.'s PE ratio is 59.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.32x versus 26.93x for OpGen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.32x -- $19.6M -$31.7M OPGNOpGen, Inc.26.93x 59.99x -- -$608.7K
-
Which has Higher Returns LAB or USAQ?
QHSLab, Inc. has a net margin of -162.05% compared to Standard BioTools, Inc.'s net margin of 4.53%. Standard BioTools, Inc.'s return on equity of -24.44% beat QHSLab, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABStandard BioTools, Inc.48.51% -$0.09 $427M USAQQHSLab, Inc.64.52% $0.00 $970.2K -
What do Analysts Say About LAB or USAQ?
Standard BioTools, Inc. has a consensus price target of $1.55, signalling upside risk potential of 37.17%. On the other hand QHSLab, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Standard BioTools, Inc. has higher upside potential than QHSLab, Inc., analysts believe Standard BioTools, Inc. is more attractive than QHSLab, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABStandard BioTools, Inc.1 2 0 USAQQHSLab, Inc.0 0 0 -
Is LAB or USAQ More Risky?
Standard BioTools, Inc. has a beta of 1.290, which suggesting that the stock is 28.967% more volatile than S&P 500. In comparison QHSLab, Inc. has a beta of 0.510, suggesting its less volatile than the S&P 500 by 48.993%.
-
Which is a Better Dividend Stock LAB or USAQ?
Standard BioTools, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QHSLab, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Standard BioTools, Inc. pays -- of its earnings as a dividend. QHSLab, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LAB or USAQ?
Standard BioTools, Inc. quarterly revenues are $19.6M, which are larger than QHSLab, Inc. quarterly revenues of $737.1K. Standard BioTools, Inc.'s net income of -$31.7M is lower than QHSLab, Inc.'s net income of $33.4K. Notably, Standard BioTools, Inc.'s price-to-earnings ratio is -- while QHSLab, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Standard BioTools, Inc. is 3.32x versus 3.39x for QHSLab, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABStandard BioTools, Inc.3.32x -- $19.6M -$31.7M USAQQHSLab, Inc.3.39x -- $737.1K $33.4K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
